A Phase 3, multicenter, open label extension trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Grants and Contracts Details

StatusFinished
Effective start/end date11/25/15 → 6/3/21

Funding

  • Quintiles Inc: $57,282.00